文献速递免疫规划传染病防控与疫情报告

XBB.1.5单价加强疫苗可刺激健康成人口腔黏膜和全身免疫应答

XBB 1.5 monovalent booster vaccination stimulates oral mucosal and systemic immune responses in healthy adults.
PubMed 文献 · Vaccine · 2026-02-21

该研究分析28名健康成人接种XBB.1.5 mRNA疫苗前后血清和唾液样本,发现接种后血清中和抗体滴度对Wuhan和XBB.1.5分别升高2.9倍和5.0倍,唾液ACE2中和活性对XBB.1.5和Wuhan分别升高1.7倍和1.4倍,且唾液中和提升主要由IgA1介导。

要点

  • XBB.1.5单价mRNA疫苗可同时提升血清和唾液中和抗体水平。
  • 唾液中和提升主要由IgA1介导,IgG贡献较小。
  • 唾液中和提升与既往感染、疫苗类型及人口学特征无关。

核心结论

  • XBB.1.5单价疫苗增强血液和黏膜中和抗体水平,对XBB.1.5变异株增幅最大。
  • 口腔黏膜免疫应答改善可能降低COVID-19感染和重症风险。

研究设计与样本

  • 研究分析28名参与者接种XBB.1.5 mRNA疫苗前一周及后2-3周的血清和唾液样本。

主要发现

  • 接种后血清中和滴度对Wuhan升高2.9倍,对XBB.1.5升高5.0倍。
  • 唾液ACE2中和活性对XBB.1.5升高1.7倍(p < 0.0001),对Wuhan升高1.4倍(p = 0.03)。
  • 唾液中和提升与既往感染次数和时间、疫苗接种状态、疫苗类型、年龄、性别及S特异性IgG升高无关。
  • 唾液XBB.1.5中和增幅最大者S特异性sIgA升高趋势更明显。
  • 耗竭唾液IgA1后ACE2阻断活性平均降低68%(范围58-81%),耗竭IgG后平均降低27%(范围0-71%)。

临床怎么用

  • XBB.1.5单价加强疫苗可考虑用于同时提升全身和口腔黏膜对XBB.1.5的中和抗体。
  • 评估黏膜免疫时唾液中和抗体(尤其IgA1)可作为补充指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The FDA approved the first monovalent XBB1.5 booster vaccine in September 2023. However, whether this vaccine stimulates mucosal immune responses in the oropharynx, especially neutralizing antibodies, remains understudied. METHODS: We analyzed serum and saliva samples from 28 participants, collected one week before and two to three weeks after the XBB1.5 mRNA vaccination, for neutralizing and binding antibodies to Wuhan and XBB1.5 Spike (S) protein. RESULTS: We observed a 2.9-fold increase in Wuhan and a 5.0-fold rise in XBB1.5 serum neutralization titers after mRNA vaccination, which correlated with increased binding antibody levels against the S protein variants in serum. We also examined saliva to assess oral mucosal immune responses to vaccination. Vaccination caused a 1.7-fold increase in ACE2 neutralization in saliva against XBB1.5 (p < 0.0001) and a 1.4-fold increase against Wuhan (p = 0.03). This rise in neutralizing antibody levels in saliva was not associated with the number and timing of previous COVID-19 infections, vaccination status, vaccine type, age, sex, or increases in S-specific IgG in either saliva or serum. Individuals with the largest increase in XBB1.5 neutralization in saliva tended to show a greater rise in S-specific sIgA levels. Depletion of salivary IgA1 or IgG after vaccination revealed that IgA1 was mainly responsible for the increase in ACE2 blocking activity (average reduction in blocking activity with IgA1 depletion = 68%, range 58-81%) compared to IgG (average reduction = 27%, range 0-71%). CONCLUSIONS: The XBB1.5 monovalent vaccine boosts neutralizing antibody levels in blood and mucous membranes, with the largest increase observed against the XBB1.5 variant. This likely reflects the enhancement of cross-reactive antibodies influenced by prior exposure and hybrid immunity, rather than the production of entirely XBB1.5-specific responses. Improved oral mucosal immune responses may reduce the risk of COVID-19 infection and severe illness.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Deraz N, Payne M, See E, et al. XBB 1.5 monovalent booster vaccination stimulates oral mucosal and systemic immune responses in healthy adults. Vaccine. 2026. PMID: 41723919. doi:10.1016/j.vaccine.2026.128346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。